

Conflict of interest statement

Name of journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 32111

Manuscript Type: Original Article

Observational Study

Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice

Shomron Ben-Horin M.D. ^{1,2} , Jane M. Andrews M.D. ³, Konstantinos H. Katsanos M.D. Ph.D ⁴, Florian Rieder M.D. Ph.D ⁵, Flavio Steinwurz M.D. ⁶, Konstantinos Karmiris M.D. Ph.D ⁷, Jae Hee Cheon M.D. Ph.D ⁸, Gordon William Moran M.D. ⁹, Monica Cesarini M.D. ¹⁰, Christian D. Stone M.D. ¹¹, Doron Schwartz M.D. ¹², Marijana Protic M.D. Ph.D ¹³, Xavier Roblin M.D. ¹⁴, Giulia Roda M.D. ¹⁵, Minhu Chen M.D. Ph.D. ², Ofir Har-Noy M.D. ¹ & Charles N. Bernstein M.D. ¹⁶

SBH has received consultancy and/or advisory board fees from Schering-Plough, AbbVie, Celltrion, Pfizer, Ferring, Janssen and Takeda; and has received research support from Celltrion, AbbVie & Takeda. KHK has received consultancy and/or advisory board fees from AbbVie, AENORASIS, MSD and Takeda. . FR has received consultancy and/or advisory board fees from AbbVie and UCB and is on the speakers bureau for AbbVie. OH has received research support from Ferring. CNB is supported in part by the Bingham Chair in Gastroenterology. He has served on advisory boards for Abbvie Canada, Ferring Canada, Janssen Canada, Shire Canada, Pfizer Canada and Takeda Canada. He has consulted to Mylan Pharmaceuticals and Bristol Myers Squibb. He has received unrestricted educational grants from Abbvie Canada, Janssen Canada, Shire Canada, and Takeda Canada. He has been on speaker's bureau for Abbvie Canada and Shire Canada. MP has received consultancy fees from MSD, AbbVie and Sandoz. JMA has served on Advisory Boards, prepared educational material &/or spoken at medical education meetings for Abbvie, Abbott, Aspen, AstraZeneca, Ferring, Janssen, MSD, Pfizer, Shire, Takeda, Hospira. She has received research funding (in last 36 months) via her institution from Abbvie, Gutsy Foundation, NMHRC, Janssen. GWM has received: Consultancy fees from AbbVie, Takeda Pharmaceuticals, Janssen and Dr Falk; Speaker fees from Merck Sharp, Dohme Ltd, AbbVie, Ferring and Takeda Pharmaceuticals and Financial support for educational activities from AbbVie, Merck Sharp, Dohme Ltd, Ferring and Dr Falk. FS has received research support and/or advisory

board/speaker fees from Abbvie, Astrazeneca, Ferring, Gilead, Janssen, Pfzier, Takeda, UCB. KK has received speaker's and/or advisory board fees from Abbvie,MSD and Takeda. XR has received research support and/or advisory board/speaker fees from Abbvie, Ferring, Janssen, , Takeda, MSD, Abbvie. MHC has received speaker fees from Xian-Janssen, Beaufour Ipsen (Tianjin China), Abbvie and Takeda. DS has received consultancy fees from Rafa Ltd and Janssen and speakers fee from Abbvie and Takeda. CDS received speaker's fees from Abbvie, Janssen, Shire, Takeda. The other authors have no conflicts of interest to disclose


Shomron Ben-Horin M.D.
Specialist, Internal Medicine
Gastroenterology & Liver Diseases
I.N. 32234 S.L.N. 23077